III.5 One year follow-up study for hallucinations in patients with Parkinson's Disease

2006 ◽  
Vol 12 ◽  
pp. 10
Author(s):  
M. Svetel ◽  
T. Smiljkovic ◽  
T. Pekmezovic ◽  
N. Dragasevic ◽  
V. Kostic
2011 ◽  
Vol 310 (1-2) ◽  
pp. 197-201 ◽  
Author(s):  
Asunción Ávila ◽  
Xavier Cardona ◽  
Montse Martín-Baranera ◽  
Juan Bello ◽  
Francesc Sastre

2013 ◽  
Vol 2013 ◽  
pp. 1-14 ◽  
Author(s):  
Susanna Jakobson Mo ◽  
Jan Linder ◽  
Lars Forsgren ◽  
Henrik Holmberg ◽  
Anne Larsson ◽  
...  

We prospectively evaluated the diagnostic contribution of123I-FP-Cit (DAT) and123I-IBZM (IBZM) SPECT in 29 patients with Parkinson's disease (PD) (74.4±4.2years) and 28 patients with atypical parkinsonian diseases (APD) (74.3±9.2years). Twelve had multiple system atrophy (MSA) and 16 progressive supranuclear palsy (PSP). Sixteen age-matched healthy controls (HC) were included. DAT and IBZM SPECTs were made at baseline and after 1 year in all PD patients and in 20 (DAT) and 18 (IBZM) of the APD patients, and after 3 years in 22 (DAT) and 17 (IBZM) of the PD patients and in 10 (DAT) and 10 (IBZM) of the APD patients. The relative DAT uptake decrease was faster in PD and PSP than in HC and MSA. In PSP the DAT uptake was lower than in MSA after 1 year but not after 3 years. Baseline IBZM uptake was not significantly different between patients and HC or between PD and APD. One year after initiated dopaminergic treatment the mean IBZM uptake in the MSA patients remained high compared to PSP and after 3 years compared to PD, PSP, and HC. Thus, the pattern of uptake of these ligands over time may be of value in discriminating between these diagnoses.


2006 ◽  
Vol 12 ◽  
pp. 30-31
Author(s):  
M. Svetel ◽  
T. Smiljkovic ◽  
T. Pekmezovic ◽  
N. Dragasevic ◽  
V. Kostic

2014 ◽  
Vol 4 (0) ◽  
pp. 216 ◽  
Author(s):  
Maurizio Giorelli ◽  
Junia Bagnoli ◽  
Luigi Consiglio ◽  
Pasquale Difazio ◽  
Daniela Zizza ◽  
...  

Cephalalgia ◽  
2016 ◽  
Vol 36 (14) ◽  
pp. 1316-1323 ◽  
Author(s):  
Hsin-I Wang ◽  
Yu-Chun Ho ◽  
Ya-Ping Huang ◽  
Shin-Liang Pan

Background The association between migraine and Parkinson’s disease (PD) remains controversial. The purpose of the present population-based, propensity score-matched follow-up study was to investigate whether migraineurs are at a higher risk of developing PD. Methods A total of 41,019 subjects aged between 40 and 90 years with at least two ambulatory visits with a diagnosis of migraine in 2001 were enrolled in the migraine group. A logistic regression model that included age, sex, pre-existing comorbidities and socioeconomic status as covariates was used to compute the propensity score. The non-migraine group consisted of 41,019 propensity score-matched, randomly sampled subjects without migraine. The PD-free survival rate were estimated using the Kaplan–Meier method. Stratified Cox proportional hazard regression was used to estimate the effect of migraine on the risk of developing PD. Results During follow-up, 148 subjects in the migraine group and 101 in the non-migraine group developed PD. Compared to the non-migraine group, the hazard ratio of PD for the migraine group was 1.64 (95% confidence interval: 1.25–2.14, p = 0.0004). The PD-free survival rate for the migraine group was significantly lower than that for the non-migraine group ( p = 0.0041). Conclusions This study showed an increased risk of developing PD in patients with migraine.


2014 ◽  
Vol 122 (6) ◽  
pp. 789-797 ◽  
Author(s):  
Uwe Walter ◽  
Robert Heilmann ◽  
Lara Kaulitz ◽  
Tino Just ◽  
Bernd Joachim Krause ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document